Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2018 09:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease

SAN FRANCISCO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries...
January 23, 2018 09:59 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Patent Issuance Opens Potential to genetically modify cells used to produce ESS Peer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....
January 09, 2018 10:59 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018

Convertible securities holders grant 45-day extension to complete Tender Exchange Elto Pharma recruiting seasoned management to lead "Go-Public" transaction Management...
January 04, 2018 09:45 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Patent Issuance Opens Potential to genetically modify cells used to produce ESSPeer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....
January 03, 2018 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data

Patents extend MANF Therapeutics' exclusivity for use of MANF as a treatment and a biomarker for beta cell disorders in Europe and China into 2032List of diseases covered by patents include Type-1...
December 26, 2017 07:30 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma

Patents extend MANF Therapeutics' exclusivity for MANF and CDNF treatment of retinal disorders in Europe into 2031Literature Watch "Super-MANF" article published in American Journal of Transplantation...
December 20, 2017 09:02 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease

Issued claims include therapeutic protein, gene therapy and cell therapy applicationsPatent extends MANF Therapeutics' exclusivity for MANF treatment of Parkinson's disease in Japan into 2029 SAN...
December 14, 2017 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF

Data demonstrates MANF's role in modulating the immune microenvironment in the retina and its potential for treating retinal disordersPatent extends MANF Therapeutics' exclusivity for MANF and CDNF...
December 11, 2017 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes

Allowed claims include the treatment of Type 1 and Type 2 DiabetesOnce issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Amarantus...
December 08, 2017 10:27 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID

Patents extend Eltoprazine Parkinson’s disease LID treatment exclusivity into 2033 SAN FRANCISCO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based...